Deals Of The Week: Merck Serono/Compugen, Lilly/PrimeraDx, Biogen Idec/Isis
With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.
You may also be interested in...
The Unlikely Renaissance Of Gene Therapy
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?
Merck/AstraZeneca Stay Tied To Each Other For Another Two Years
Merck and AstraZeneca continue a 30-year partnership after coming to terms that could benefit both companies.
Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.